OSTEOBiol GTO: A NEW STEP TOWARDS EXCELLENCE IN BIOMATERIALS

At the beginning of this year, Tecnoss Dental, a leading biomaterials manufacturer based in Italy, launched a new bone substitute which combines innovative and advanced biotechnology, providing implantologists and periodontists with a grafting solution with improved surgical handling and predictable regenerative results. OsteoBiol GTO is endowed with all the characteristics of the ideal biomaterial for bone regeneration. This pioneering product is able to promote the three biological processes which guide bone regeneration: new bone apposition, neo-angiogenesis and progressive resorption of the scaffolding material, in order to promote adequate new bone formation. Tecnoss is showcasing GTO at this year’s EAO congress.

GTO is a dual-phase biomaterial, because its granules contain both mineral and organic components. The preservation of collagen within the original xenogenic cortical and cancellous bone matrix induces a physiological biological response by the patient’s bone tissue. Collagen has several significant advantages for bone regeneration, all scientifically well documented: it stimulates mesenchymal stem cell differentiation into osteoblasts, it is chemotactic, and it stimulates neo-angiogenesis and the absorption and subsequent release of growth factors. All these important biological benefits have determined the scientific rationale behind Tecnoss’s 20-year long research and development effort to produce a full range of collagenated dual-phase bone substitutes.

The development of GTO is the last step of the process of continuous improvement by Tecnoss, starting with Apatos Cortical, a very osteoconductive but slowly resorbed scaffolding biomaterial. The first real breakthrough innovation has been Gen-Os, which is the precursor of all the dual-phase products. The outstanding OsteoBiol mp3 then followed as the first pre-hydrated bone substitute, packed in a ready-to-use syringe. In 2016, OsteoBiol TSV Gel, the thermostensitive viscosity resorbable gel which is used to create a sticky bone mix with Gen-Os, was launched. GTO combines all of the company's experience and expertise in a unique product which is extremely versatile and achieves outstanding biological performance.

GTO has an ideal viscosity, which means that it is very sticky and easily adaptable to the recipient site, making it a great option for treating various types of complex bone lesions. Its syringe formulation means that it is ready to use and is directly injectable into bone defects, making its handling easy and quick. GTO has been conceived as a universal biomaterial for use with OsteoBiol Evolution membranes or Lamin to protect the graft. Its stickiness and stability are useful properties for horizontal augmentation procedures (e.g., two-wall defects, where the crest is restored) and for socket preservation cases with compromised buccal plates. During sinus lifting, GTO can be applied directly through the bony window, helping the stabilization of implants in case of immediate placement. GTO can also be successfully used to treat peri-implant lesions, dehiscences and severe intra-bony defects.

The product is already available in all EU countries and in other European markets where the OsteoBiol product line is distributed. For further information, visit www.osteobiol.com/contact.

For more information, visit www.osteobiol.com/contact.
The INVERTA implant represents the latest breakthrough technology from Southern Implants and is designed for optimizing aesthetics in maxillary anterior extraction socket sites. At EAO 2019, the company is showcasing its newest product.

The INVERTA implant features a novel Body-Shift design that addresses challenges many clinicians face with immediate anterior implant procedures. The innovative design of the inverted coronal segment of the implant allows for a chamber for bone growth to be created, thereby enhancing the ability to obtain natural-looking aesthetics. The wider apical portion allows the implant to achieve the primary stability critical in immediate placement.

INVERTA also incorporates proven features from Southern Implants’ other implant product lines, such as its SInergy Surface with decades of clinical research and high-strength Grade 4 pure titanium, which provides exceptional fatigue strength. The new implant is available with the popular deep conical internal and external hex connections. For treatment flexibility, INVERTA is available in a straight configuration and 12° Co-Axis, the latter offering built-in Subcrestal Angle Correction without using angled abutments, resulting in greater facial soft-tissue volume and providing ideal screw-retained restorative options.

Dr Pär-Olov Östman, a respected opinion leader who practises in Falun, Sweden, commented on the innovative implant design: “To be able to use INVERTA implants in aesthetically challenging cases gives me a predictable outcome with limited buccal recession and healthy soft tissue.”

The following clinical research articles on INVERTA have been published and more articles are expected to be released throughout 2019 and beyond:


For more information during EAO 2019, please visit the company’s booth.

Southern Implants, South Africa
www.southernimplants.com
Hall 2, Booth A26
Similarly to the way in which a GPS system guides a driver, Navident by ClaroNav guides clinicians by using the CBCT image as a map. It offers surgeons an easy-to-use, accurate, highly portable and affordable means of planning restorations and implant placements.

With Navident 2, clinicians will no longer need to do a special extra scan. They can use the diagnostic scan already available for the patient. The stress of stent making is also gone because a stent is no longer required.

Trace and Place (TaP) is a game-changing development for dynamic navigation. With TaP, the Navident workflow is streamlined, efficient, user-friendly and seamlessly integrated into the daily practice.

“Trace and Place is a real tipping point for dynamic navigation guidance,” said user Dr George Mandelaidis, a periodontist from Chicago in the US. “It has streamlined and simplified the workflow in both the diagnostic and surgical phases to allow state-of-the-art technology to be an everyday component of my surgical implant practice. I cannot imagine going back!”

Implantology specialists who have used Navident 2.0 experienced negligible operator stress, improved time efficiency and an increase in patient acceptance. The accuracy offered by the new version, combined with the need for minimal tissue manipulation, is conducive to a shorter and better recovery process for patients, according to the company.

Clinicians are invited to learn from masters and interact with their peers at ClaroNav’s booth at this year’s EAO meeting.

ClaroNav, Canada
www.claronav.com
Hall 2, Booth C09

**Simplified Workflow with TaP (Trace Registration)**

... which can be performed in a single appointment